Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Extends Bid for Orchid Cellmark for Ninth Time

NEW YORK (GenomeWeb News) – Laboratory Corporation of America has extended its cash tender offer for Orchid Cellmark for the ninth time as it continues to address questions from regulators about the proposed $85.4 million deal.

Today, LabCorp said it has extended its cash tender offer to 5 p.m. Nov. 30, after its prior extension to Nov.14 expired. In a statement, the company said that continues to cooperate with the Federal Trade Commission's request for additional information.

Also, it said that in order to allow more time to complete the deal, LabCorp, its subsidiary, OCM Acquisition, and Orchid have amended their merger agreement to extend the Extended Outside Date of the offer by an additional 30 calendar days to Dec. 14.

The depositary for the tender offer has told LabCorp that as of 5 p.m. Nov. 14, shareholders of Orchid had validly tendered and not withdrawn 26,064,267 shares of the company's stock, or about 86.8 percent of Orchid's outstanding shares. On a fully diluted basis, the figure represents about 79.7 percent of Orchid shares.

There were no shares tendered through uncovered notices of guaranteed delivery.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.